Rivus Pharmaceuticals

Rivus Pharmaceuticals, Inc. is dedicated to improving cardiometabolic health by advancing a new class of investigational medicines called controlled metabolic accelerators (CMAs). These oral small molecules are designed to reduce excess fat and treat a broad range of cardiometabolic diseases by safely leveraging the natural process of mitochondrial uncoupling. Activating this metabolic process results in fat-specific weight loss, preservation of muscle mass, reduction of liver and visceral fat, improved glycemic control and reductions in oxidative stress and inflammation. Rivus’ lead CMA, HU6, is in development to treat obesity and associated cardiometabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD) / metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes. Rivus’ discovery platform which combines an uncoupling AI/ML classifier model trained on proprietary datasets has yielded additional CMA candidates for preclinical development in therapeutic areas with significant need.